Global Blood Therapeutics - GBT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $65.42
  • Forecasted Upside: -4.48%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
+0 (0.00%)
Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

Analyst Price Target is $65.42
▼ -4.48% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $65.42, with a high forecast of $75.00 and a low forecast of $31.00. The average price target represents a -4.48% upside from the last price of $68.49.

This chart shows the closing price for GBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 polled investment analysts is to hold stock in Global Blood Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 11 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 11 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2022Cantor FitzgeraldReiterated RatingNeutralLow
8/15/2022GuggenheimBoost Target$72.00N/A
8/15/2022Truist FinancialDowngradeHoldN/A
8/15/2022OppenheimerDowngradeMarket PerformN/A
8/9/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/9/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$68.50Low
8/9/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$66.00 ➝ $68.50Low
8/9/2022CowenDowngradeMarket Perform$67.00 ➝ $68.50Low
8/8/2022WedbushReiterated RatingOutperform ➝ NeutralLow
8/8/2022Stifel NicolausReiterated RatingBuy ➝ HoldLow
8/8/2022William BlairDowngradeOutperform ➝ Market PerformLow
8/8/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$40.00 ➝ $72.00Low
8/8/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$40.00 ➝ $72.00Low
6/28/2022JPMorgan Chase & Co.Lower TargetNeutral$39.00 ➝ $36.00Low
6/20/2022WedbushSet Target$74.00Low
5/5/2022OppenheimerLower Target$86.00 ➝ $71.00High
4/28/2022Cantor FitzgeraldInitiated CoverageBuy$75.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/28/2022WedbushReiterated RatingOutperformHigh
2/28/2022Morgan StanleyBoost TargetEqual Weight$28.00 ➝ $31.00Medium
2/24/2022HC WainwrightReiterated RatingBuy$75.00High
2/24/2022CowenLower Target$72.00 ➝ $67.00High
2/24/2022OppenheimerLower TargetOutperform$92.00 ➝ $86.00High
12/21/2021SVB LeerinkLower TargetOutperform$56.00 ➝ $53.00Low
12/14/2021SVB LeerinkBoost TargetOutperform$54.00 ➝ $56.00High
12/7/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
11/5/2021Royal Bank of CanadaLower TargetOutperform$66.00 ➝ $64.00High
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$68.00High
9/8/2021WedbushReiterated RatingBuyLow
8/4/2021Truist FinancialUpgradeBuy$45.00 ➝ $50.00High
8/4/2021Piper SandlerLower TargetNeutral$45.00 ➝ $40.00High
6/28/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00 ➝ $36.00High
5/7/2021Cantor FitzgeraldLower TargetOverweight$120.00 ➝ $110.00Low
5/6/2021Piper SandlerLower Target$50.00 ➝ $45.00High
5/6/2021Roth CapitalLower TargetBuy$128.00 ➝ $124.00High
4/14/2021SVB LeerinkInitiated CoverageOutperform$54.00Low
3/11/2021Wolfe ResearchInitiated CoverageOutperform$67.00Low
2/25/2021William BlairDowngradeOutperform ➝ Market PerformHigh
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$75.00 ➝ $50.00Low
12/16/2020Morgan StanleyLower TargetEqual Weight$67.00 ➝ $45.00Low
12/15/2020HC WainwrightReiterated RatingBuy$75.00Low
12/8/2020William BlairReiterated RatingBuyMedium
12/3/2020Royal Bank of CanadaInitiated CoverageOutperform$75.00High
11/18/2020Cantor FitzgeraldLower TargetOverweight$133.00 ➝ $120.00Low
11/9/2020Truist FinancialLower Target$78.00 ➝ $55.00Low
11/6/2020Morgan StanleyLower TargetEqual Weight$68.00 ➝ $67.00High
11/6/2020Roth CapitalLower TargetBuy$131.00 ➝ $128.00High
11/6/2020Stifel NicolausLower TargetBuy$120.00 ➝ $101.00High
11/6/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $120.00High
11/6/2020OppenheimerLower TargetOutperform$102.00 ➝ $92.00High
11/6/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
10/13/2020Morgan StanleyLower TargetEqual Weight$75.00 ➝ $68.00High
10/6/2020Evercore ISIInitiated CoverageOutperform$102.00Medium
8/25/2020WedbushBoost Target$145.00 ➝ $152.00Medium
8/24/2020Raymond JamesInitiated CoverageOutperform$115.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$150.00Low
8/6/2020Stifel NicolausBoost TargetBuy$113.00 ➝ $118.00High
7/29/2020Piper SandlerReiterated RatingBuy$120.00Low
7/20/2020Roth CapitalInitiated CoverageBuy$129.00Low
7/13/2020Bank of AmericaInitiated CoverageBuy$92.00High
7/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $103.00High
6/25/2020HC WainwrightReiterated RatingBuy$150.00Low
6/23/2020WedbushReiterated RatingBuy$145.00High
6/15/2020OppenheimerReiterated RatingBuy$101.00High
6/12/2020Wells Fargo & CompanyReiterated RatingBuyHigh
5/12/2020WedbushReiterated RatingBuy$145.00Low
5/7/2020Cantor FitzgeraldBoost Target$105.00 ➝ $130.00Low
5/7/2020NomuraReiterated RatingBuy$112.00Low
5/7/2020Wells Fargo & CompanyBoost TargetOverweight$122.00 ➝ $133.00Medium
5/7/2020OppenheimerBoost TargetOutperform$88.00 ➝ $101.00Low
5/7/2020Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $75.00High
4/27/2020Stifel NicolausInitiated CoverageBuy$112.00Low
4/15/2020Morgan StanleyLower TargetEqual Weight$71.00 ➝ $70.00Low
3/19/2020WedbushReiterated RatingBuy$145.00Medium
3/18/2020OppenheimerLower Target$100.00 ➝ $88.00Low
3/3/2020Morgan StanleyLower TargetEqual Weight$80.00 ➝ $71.00High
1/31/2020SunTrust BanksDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
1/17/2020Morgan StanleyBoost TargetEqual Weight$79.00 ➝ $80.00Medium
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$120.00N/A
12/22/2019WedbushReiterated RatingBuy$143.00Medium
12/18/2019William BlairReiterated RatingBuyHigh
12/17/2019JPMorgan Chase & Co.Boost TargetEqual Weight$58.00 ➝ $79.00Low
12/10/2019Piper Jaffray CompaniesBoost Target$95.00 ➝ $120.00High
12/9/2019OppenheimerReiterated RatingBuy$100.00Low
11/26/2019Nomura SecuritiesBoost TargetBuy$109.00 ➝ $112.00High
11/26/2019WedbushReiterated RatingBuy$143.00High
11/26/2019Janney Montgomery ScottBoost TargetBuy$75.00 ➝ $90.00High
11/26/2019SunTrust BanksBoost TargetBuy$110.00High
11/26/2019Piper Jaffray CompaniesBoost TargetOverweight$80.00 ➝ $95.00High
11/25/2019Cantor FitzgeraldReiterated RatingBuy$110.00 ➝ $98.00High
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
10/14/2019SunTrust BanksBoost TargetBuy$100.00Low
10/9/2019CowenSet TargetBuy$83.00Low
10/9/2019WedbushReiterated RatingBuy$120.00Low
10/9/2019Wells Fargo & CompanyBoost TargetOutperform$96.00 ➝ $104.00Medium
10/9/2019HC WainwrightReiterated RatingBuy$150.00Medium
10/8/2019William BlairReiterated RatingBuyLow
9/12/2019WedbushReiterated RatingBuy$120.00Medium
9/6/2019HC WainwrightSet TargetBuy$150.00Low
9/5/2019CowenSet TargetBuy$83.00Low
9/5/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/5/2019WedbushBoost TargetOutperform ➝ Hold$103.00 ➝ $120.00High
8/12/2019WedbushReiterated RatingOutperform$103.00Low
8/11/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
8/9/2019Morgan StanleySet TargetHold$60.00Medium
8/8/2019CowenReiterated RatingBuy$83.00Low
8/8/2019HC WainwrightReiterated RatingBuy$150.00Low
6/28/2019WedbushSet TargetBuy$103.00Medium
6/25/2019HC WainwrightReiterated RatingBuyLow
6/17/2019WedbushReiterated RatingBuy$107.00Medium
6/16/2019CowenReiterated RatingBuyMedium
6/14/2019Cantor FitzgeraldSet TargetBuy$96.00 ➝ $110.00High
6/11/2019WedbushReiterated RatingBuy$107.00Low
6/3/2019WedbushReiterated RatingBuy$95.00 ➝ $107.00High
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$75.00Low
5/13/2019WedbushReiterated RatingBuy$95.00High
5/9/2019OppenheimerBoost TargetOutperform$82.00 ➝ $89.00Medium
4/18/2019WedbushReiterated RatingOutperform$95.00Medium
4/12/2019HC WainwrightSet TargetBuy$150.00High
4/1/2019Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$85.00 ➝ $96.00Low
3/5/2019WedbushBoost TargetOutperform ➝ Outperform$91.00 ➝ $95.00Low
3/4/2019Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$55.00 ➝ $57.00Low
2/28/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
2/22/2019GuggenheimInitiated CoverageBuy$75.00Low
1/30/2019William BlairReiterated RatingBuyHigh
12/19/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$54.00 ➝ $55.00High
12/4/2018SunTrust BanksBoost TargetBuy ➝ Positive$90.00Medium
12/4/2018HC WainwrightSet TargetBuy$150.00Medium
12/3/2018William BlairReiterated RatingBuyHigh
12/3/2018Cantor FitzgeraldSet TargetBuy$96.00High
12/3/2018OppenheimerSet TargetBuy$82.00High
11/28/2018HC WainwrightReiterated RatingBuy ➝ Buy$150.00High
11/19/2018WedbushReiterated RatingBuy$73.00Low
11/7/2018OppenheimerSet TargetBuy$74.00 ➝ $82.00High
11/7/2018William BlairReiterated RatingBuyHigh
11/5/2018HC WainwrightSet TargetBuy$125.00Low
11/1/2018OppenheimerSet TargetBuy$74.00Medium
10/23/2018Cantor FitzgeraldSet TargetBuy$96.00Low
10/19/2018HC WainwrightSet TargetBuy$125.00High
10/18/2018William BlairReiterated RatingBuyHigh
10/17/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
10/2/2018Cantor FitzgeraldSet TargetBuy$96.00High
9/13/2018HC WainwrightSet TargetBuy$125.00High
8/23/2018Cantor FitzgeraldSet TargetBuy$96.00Medium
8/23/2018HC WainwrightSet TargetBuy$125.00Low
8/13/2018CowenReiterated RatingBuy$83.00High
8/8/2018HC WainwrightSet TargetBuy$125.00Low
8/8/2018Cantor FitzgeraldReiterated RatingBuy$96.00Low
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$73.00Low
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
8/5/2018SunTrust BanksSet TargetBuy$70.00Low
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
8/2/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
7/27/2018HC WainwrightReiterated RatingBuy$125.00High
6/28/2018Nomura SecuritiesBoost TargetBuy ➝ Buy$91.00 ➝ $109.00High
6/27/2018HC WainwrightBoost TargetBuy ➝ Buy$73.00 ➝ $125.00High
6/27/2018Wells Fargo & CompanyBoost TargetOutperform$78.00 ➝ $85.00High
6/27/2018Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$69.00 ➝ $96.00High
6/18/2018WedbushReiterated RatingOutperform$70.00Low
5/24/2018HC WainwrightSet TargetBuy$73.00Low
5/21/2018WedbushReiterated RatingOutperform$70.00High
5/10/2018HC WainwrightSet TargetBuy$73.00Medium
5/9/2018Cantor FitzgeraldSet TargetBuy$69.00Medium
5/8/2018SunTrust BanksLower TargetBuy ➝ Buy$80.00 ➝ $77.00High
5/8/2018OppenheimerLower TargetOutperform ➝ Outperform$79.00 ➝ $74.00High
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00High
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$61.00High
3/14/2018WedbushReiterated RatingOutperform$73.00Low
3/12/2018HC WainwrightSet TargetBuy$73.00High
3/6/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$58.00 ➝ $61.00Low
3/1/2018SunTrust BanksSet TargetPositive ➝ Buy$80.00Medium
2/28/2018William BlairReiterated RatingBuyHigh
2/28/2018HC WainwrightSet TargetBuy$73.00High
2/27/2018Cantor FitzgeraldSet TargetOverweight ➝ Overweight$61.00 ➝ $72.00High
2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Global Blood Therapeutics logo
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $68.49
Low: $68.49
High: $68.49

50 Day Range

MA: $68.47
Low: $68.07
High: $68.49

52 Week Range

Now: $68.49
Low: $21.65
High: $73.02


74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Stifel Nicolaus,, SVB Leerink LLC, Truist Financial Co., Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for GBT.

What is the current price target for Global Blood Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. Their average twelve-month price target is $65.42, suggesting a possible downside of 4.5%. Cantor Fitzgerald has the highest price target set, predicting GBT will reach $75.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $31.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.

What is the current consensus analyst rating for Global Blood Therapeutics?

Global Blood Therapeutics currently has 11 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GBT, but not buy more shares or sell existing shares.
View the latest ratings for GBT.

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?

Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 741-7700 and its investor relations email address is [email protected] The official website for Global Blood Therapeutics is Learn More about contacing Global Blood Therapeutics investor relations.